PL EN


Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników
2005 | 52 | 3 |
Tytuł artykułu

Helper-dependent adenoviral vectors in experimental gene therapy

Treść / Zawartość
Warianty tytułu
Języki publikacji
EN
Abstrakty
EN
In the majority of potential applications gene therapy will require an effective transfer of a transgene in vivo resulting in high-level and long-term transgene expression, all in the absence of significant toxicity or inflammatory responses. The most efficient vehicles for delivery of foreign genes to the target tissues are modified adenoviruses. Adenoviral vectors of the first generation, despite the high infection efficacy, have an essential drawback: they induce strong immune response, which leads to short term expression of the transgene, and limits their usefulness in clinical trials. In contrast, helper-dependent adenoviral vectors (HdAd) lacking all viral coding sequences display only minimal immunogenicity and negligible side-effects, allowing for long-term transgene expression. Thus, HdAd vehicles have become the carrier of choice for adenoviral vector-mediated experimental gene therapy, effectively used in animal models for delivery of transgenes into the liver, skeletal muscle, myocardium or brain. Strong and long-lasting expression of therapeutic genes has allowed for successful treatment of dyslipidemias, muscular dystrophy, obesity, hemophilia, and diabetes. Additionally, the large cloning capacity of HdAd, up to 37 kb, facilitates the use of physiologically regulated, endogenous promoters, instead of artificial viral promoter sequences. This enables also generation of the single vectors expressing multiple genes, which can be potentially useful for treatment of polygenic diseases. In this review we characterize the basic features of HdAd vectors and describe some of their experimental and potential clinical applications.
Wydawca
-
Rocznik
Tom
52
Numer
3
Opis fizyczny
p.589-599,fig.,ref.
Twórcy
autor
  • Jagiellonian University, Krakow, Poland
autor
Bibliografia
  • Aurisicchio L, Bujard H, Hillen W, Cortese R, Ciliberto G, La Monica N, Palombo F (2001) Regulated and prolonged expression of mIFN(alpha) in immunocompe tent mice mediated by a helper-dependent adenovirus vector. Gene Ther 24: 1817–1825.
  • Balamotis MA, Huang K, Mitani K (2004) Efficient delivery and stable gene expression in a hematopoietic cell line using a chimeric serotype 35 fiber pseudotyped helperdependent adenoviral vector. Virology 324: 229–237.
  • Belalcazar LM, Merched A, Carr B, Oka K, Chen KH, Pastore L, Beaudet A, Chan L (2003) Long-term stable expression of human apolipoprotein A-I mediated by helper-dependent adenovirus gene transfer inhibits atherosclerosis progression and remodels atherosclerotic plaques in a mouse model of familial hypercholesterolemia. Circulation 107: 2726–2732.
  • Benihound K, Yeh P, Perricaudet M (1999) Adenovirus vector for gene delivery. Curr Opin Biotech 10: 440–447.
  • Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS, Horwitz MS, Crowell RL, Finberg RW (1997) Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. Science 275: 1320–1323.
  • Bramson JL, Grinshtein N, Meulenbroek RA, Lunde J, Kottachchi D, Lorimer IA, Jasmin BJ, Parks RJ (2004) Helper-dependent adenoviral vectors containing modified fiber for improved transduction of developing and mature muscle cells. Hum Gene Ther 15: 179–188.
  • Brown BD, Shi CX, Powell S, Hurlbut D, Graham FL, Lillicrap D (2004a) Helper-dependent adenoviral vectors mediate therapeutic factor VIII expression for several months with minimal accompanying toxicity in a canine model of severe hemophilia A. Blood 103: 804–810.
  • Brown BD, Shi CX, Rawle FE, Tinlin S, McKinven A, Hough C, Graham FL, Lillicrap D (2004b) Factors influencing therapeutic efficacy and the host immune response to helper-dependent adenoviral gene therapy in hemophilia A mice. J Thromb Haemost 2: 111–118.
  • Brunetti-Pierri N, Palmer DJ, Beaudet AL, Carey KD, Finegold M, Ng P (2004) Acute toxicity after high-dose systemic injection of helper-dependent adenoviral vectors into nonhuman primates. Hum Gene Ther 15: 35–46.
  • Buttgereit P, Weineck S, Ropke G, Marten A, Brand K, Heinicke T, Caselmann WH, Huhn D, Schmidt-Wolf IG (2000) Efficient gene transfer into lymphoma cells using adenoviral vectors combined with lipofection. Cancer Gene Ther 7: 1145–1155.
  • Campfield LA, Smith FJ, Guisez Y, Devos R, Burn P (1995) Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks. Science 269: 546–549.
  • Chan L (1995) Use of somatic gene transfer to study lipoprotein metabolism in experimental animals in vivo. Curr Opin Lipidol 6: 335–340.
  • Chen HH, Mack LM, Kelly R, Ontell M, Kochanek S, Clemens PR (1997) Persistence in muscle of an adenoviral vector that lacks all viral genes. Proc Natl Acad Sci USA 94: 1645–1650.
  • Chuah MK, Collen D, VandenDriessche T (2004) Clinical gene transfer studies for hemophilia A. Semin Thromb Hemost 30: 249–256.
  • St. Clair RW, Beisiegel U (1997) What do all the apolipoprotein receptors do? Curr Opin Lipidol 8: 243–245.
  • Dai Y, Schwarz EM, Gu D, Zhang WW, Sarvetnic N, Verma IM (1995) Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for longterm expression. Proc Natl Acad Sci USA 92: 1401–1405.
  • Dorigo O, Gil JS, Gallaher SD, Tan BT, Castro MG, Lowenstein PR, Calos MP, Berk AJ (2004) Development of a novel helper-dependent adenovirus-Epstein-Barr virus hybrid system for the stable transformation of mammalian cells. J Virol 78: 6556–6566.
  • Dudley RW, Lu Y, Gilbert R, Matecki S, Nalbantoglu J, Petrof BJ, Karpati G (2004) Sustained improvement of muscle function one year after full-length dystrophin gene transfer into mdx mice by a gutted helper-dependent adenoviral vector. Hum Gene Ther 15: 145–156.
  • Ehrhardt A, Kay MA (2002) A new adenoviral helper-dependent vector results in long-term therapeutic levels of human coagulation factor IX at low doses in vivo. Blood 99: 3923–3930.
  • Ehrhardt A, Xu H, Kay MA (2003) Episomal persistence of recombinant adenoviral vector genomes during the cell cycle in vivo. J Virol 13: 7689–7695.
  • Eto Y, Gao JQ, Sekiguchi F, Kurachi S, Katayama K, Mizuguchi H, Hayakawa T, Tsutsumi Y, Mayumi T, Nakagawa S (2004) Neutralizing antibody evasion ability of adenovirus vector induced by the bioconjugation of methoxypolyethylene glycol succimidyl propionate (MPEG-SPA). Biol Pharm Bull 27: 936–938.
  • Fleury S, Driscoll R, Simeoni E, Dudler J, von Segesser LK, Kappenberger L, Vassalli G (2004) Helper-dependent adenovirus vectors devoid of all viral genes cause less myocardial inflammation compared with first-generation adenovirus vectors. Basic Res Cardiol 99: 247–256.
  • Gerard RD, Chan L (1996) Adenovirus-mediated gene transfer: strategies and applications in lipoprotein research. Curr Opin Lipidol 7: 105–111.
  • Gerard RD, Collen D (1997) Adenovirus gene therapy for hypercholesterolemia, thrombosis and restenosis. Cardiovasc Res 35: 451–458.
  • Gilbert R, Dudley RW, Liu AB, Petrof BJ, Nalbantoglu J, Karpati G (2003) Prolonged dystrophin expression and functional correction of mdx mouse muscle following gene transfer with a helper-dependent (gutted) adenovirus- encoding murine dystrophin. Hum Mol Genet 12: 1287–1299.
  • Haecker SE, Stedman HH, Balice-Gordon RJ, Smith DBJ, Greelish JP, Mitchell MA, Wells A, Sweeney HL, Wilson JM (1996) In vivo expression of full-length human dystrophin from adenoviral vectors deleted of all viral genes. Hum Gene Ther 7: 1907–1914.
  • Hardy S, Kitamura M, Harris-Stansil T, Dai Y, Phipps ML (1997) Construction of adenovirus vector through crelox recombination. J Virol 71: 1842–1849.
  • Harui A, Suzuki S, Kochanek S, Mitani K (1999) Frequency and stability of chromosomal integration of adenovirus vectors. J Virol 73: 6141–6146.
  • Hillgenberg M, Tonnies H, Strauss M (2001) Chromosomal integration pattern of a helper-dependent minimal adenovirus vector with a selectable marker inserted into a 27.4-kilobase genomic stuffer. J Virol 75: 9896–9908.
  • Józkowicz A, Dulak J, Nanobashvili J, Prager M, Huk J (2002) Gutless adenoviral vectors – promising tools for gene therapy. Eur Surg 34: 95–100.
  • Kafri T, Morgan D, Krahl T, Sarvetnick N, Sherman L, Verma I (1998) Cellular immune response to adenoviral vector infected cells does not require de novo viral gene expression: implications for gene therapy. Proc Natl Acad Sci USA 95: 11377–11382.
  • Kim IH, Józkowicz A, Piedra PA, Oka K, Chan L (2001) Lifetime correction of genetic deficiency in mice with a single injection of helper-dependent adenoviral vector. Proc Natl Acad Sci USA 98: 13282–13287.
  • Kobayashi K, Oka K, Forte T, Ishida B, Teng B, Ishimura-Oka K, Nakamuta M, Chan L (1996) Reversal of hypercholesterolemia in low density lipoprotein receptor knockout mice by adenovirus-mediated gene transfer of the very low density lipoprotein receptor. J Biol Chem 271: 6852–6860.
  • Kochanek S, Clemens PR, Mitani K, Chen HH, Chan S, Caskey CT (1996) A new adenoviral vector: replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and β-galactosidase. Proc Natl Acad Sci USA 93: 5731–5736.
  • Kojima H, Fujimiya M, Matsumura K, Younan P, Imaeda H, Maeda M, Chan L (2003) NeuroD-betacellulin gene therapy induces islet neogenesis in the liver and reverses diabetes in mice. Nat Med 9: 596–603.
  • Kovesdi I, Brough DE, Bruder JT, Wickham TJ (1997) Adenoviral vectors for gene transfer. Curr Opin Biotechnol 8: 583–589.
  • Kreppel F, Kochanek S (2004) Long-term transgene expression in proliferating cells mediated by episomally maintained high-capacity adenovirus vectors. J Virol 78: 9–22.
  • Maione D, Wiznerowicz M, Delmastro P, Cortese R, Ciliberto G, La Monica N, Savino R (2000) Prolonged expression and effective readministration of erythropoietin delivered with a fully deleted adenoviral vector. Hum Gene Ther 11: 859–868.
  • Maione D, Della Rocca C, Giannetti P, D’Arrigo R, Liberatoscioli L, Franlin LL, Sandig V, Ciliberto G, La Monica N, Savino R (2001) An improved helper-dependent adenoviral vector allows persistent gene expression after intramuscular delivery and overcomes preexisting immunity to adenovirus. Proc Natl Acad Sci USA 98: 5986–5991.
  • Mian A, McCormack WM Jr, Mane V, Kleppe S, Ng P, Finegold M, O’Brien WE, Rodgers JR, Beaudet AL, Lee B (2004) Long-term correction of ornithine transcarbamylase deficiency by WPRE-mediated overexpression using a helper-dependent adenovirus. Mol Ther 10: 492–499.
  • Mitani K, Kubo S (2002) Adenovirus as an integrating vector. Curr Gene Ther 2: 135–144.
  • Mitani K, Graham FL, Caskey CT, Kochanek S (1995) Rescue, propagation, and partial purification of a helper virus-dependent adenovirus vector. Proc Natl Acad Sci USA 95: 3854–3858.
  • Mok H, Palmer DJ, Ng P, Barry MA (2005) Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses. Mol Ther 11: 66–79.
  • Morral N, Parks R, Zhou H, Langston C, Schiedner G, Quinones J, Graham FL, Kochanek S, Beaudet AL (1998) High doses of a helper-dependent adenoviral vector yield supra-physiological levels of alpha1-antitripsin with negligible toxicity. Hum Gene Ther 9: 2709–2716.
  • Morral N, O’Neal W, Rice K, Leland M, Kaplan J, Piedra PA, Zhou H, Parks RJ, Velji R, Aguilar-Cordova E, Wadsworth S, Graham FL, Kochanek S, Carey KD, Beaudet AL (1999) Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons. Proc Natl Acad Sci USA 96: 12816–12821.
  • Morsy MA, Gu MC, Zhao JZ, Holder DJ, Rogers IT, Pouch WJ, Motzel SL, Klein HJ, Gupta SK, Liang X, Tota MR, Rosenblum CI, Caskey CT (1998a) Leptin gene therapy and daily protein administration: a comparative study in the ob/ob mouse. Gene Ther 5: 8–18.
  • Morsy MA, Gu MC, Motzel S, Zhao J, Lin J, Su Q, Allen H, Franlin L, Parks RJ, Graham FL, Kochanek S, Bett AJ, Caskey CT (1998b) An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene. Proc Natl Acad Sci USA 95: 7866–7871.
  • Mountain A (2000) Gene therapy: the first decade. Trends Biotechnol 18: 119–128.
  • Muruve DA, Cotter MJ, Zaiss AK, White LR, Liu Q, Chan T, Clark SA, Ross PJ, Meulenbroek RA, Maelandsmo GM, Parks RJ (2004) Helper-dependent adenovirus vectors elicit intact innate but attenuated adaptive host immune responses in vivo. J Virol 78: 5966–5972.
  • Ng P, Evelegh C, Cummings D, Graham FL (2002) Cre levels limit packaging signal excision efficiency in the Cre/loxP helper-dependent adenoviral vector system. J Virol 76: 4181–4189.
  • Nomura S, Merched A, Nour E, Dieker C, Oka K, Chan L (2004) Low-density lipoprotein receptor gene therapy using helper-dependent adenovirus produces long-term protection against atherosclerosis in a mouse model of familial hypercholesterolemia. Gene Ther 11: 1540–1548.
  • Oka K, Pastore L, Kim IH, Merched A, Nomura S, Lee HJ, Merched-Sauvage M, Arden-Riley C, Lee B, Finegold M, Beaudet A, Chan L (2001) Long-term stable correction of low-density lipoprotein receptor-deficient mice with a helper-dependent adenoviral vector expressing the very low-density lipoprotein receptor. Circulation 103: 1274–1282.
  • Oshima Y, Oshima S, Nambu H, Kachi S, Hackett SF, Melia M, Kaleko M, Connelly S, Esumi N, Zack DJ, Campochiaro PA (2004) Increased expression of VEGF in retinal pigmented epithelial cells is not sufficient to cause choroidal neovascularization. J Cell Physiol 201: 393–400.
  • Palmer DJ, Ng P (2005) Helper-dependent adenoviral vectors for gene therapy. Hum Gene Ther 16: 1–16.
  • Parks R, Chen L, Anton M, Sankar U, Rudnicki MA, Graham FL (1996) A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc Natl Acad Sci USA 93: 13565–13570.
  • Parks RJ, Bramson JL, Wan Y, Addison CL, Graham FL (1999) Effects of stuffer DNA on transgene expression from helper-dependent adenovirus vectors. J Virol 73: 8027–8034.
  • Pastore L, Belalcazar LM, Oka K, Cela R, Lee B, Chan L, Beaudet AL (2004) Helper-dependent adenoviral vector-mediated long-term expression of human apolipoprotein A-I reduces atherosclerosis in apo E-deficient mice. Gene 327: 153–160.
  • Raper SE, Chirmule N, Lee FS, Wivel NA, Bagg A, Gao GP, Wilson JM, Batshaw ML (2003) Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 80: 148–158.
  • Raper SE, Wilson JM, Yudkoff M, Robinson MB, Ye X, Batshaw ML (1998) Developing adenoviral-mediated in vivo gene therapy for ornithine transcarbamylase deficiency. J Inherit Metab Dis 21 (Suppl 1): 119–137.
  • Recchia A, Parks RJ, Lamartina S, Toniatti C, Pieroni L, Palombo F, Ciliberto G, Graham FL, Cortese R, La Monica N, Colloca S (1999) Site-specific integration mediated by a hybrid adenovirus/adeno-associated virus vector. Proc Natl Acad Sci USA 96: 2615–2620.
  • Reddy PS, Sakhuja K, Ganesh S, Yang L, Kayda D, Brann T, Pattison S, Golightly D, Idamakanti N, Pinkstaff A, Kaloss M, Barjot C, Chamberlain JS, Kaleko M, Connelly S (2002) Sustained human factor VIII expression in hemophilia A mice following systemic delivery of a gutless adenoviral vector. Mol Ther 5: 63–73.
  • Sakhuja K, Reddy PS, Ganesh S, Cantaniag F, Pattison S, Limbach P, Kayda DB, Kadan MJ, Kaleko M, Connelly S (2003) Optimization of the generation and propagation of gutless adenoviral vectors. Hum Gene Ther 14: 243–254.
  • Schiedner G, Bloch W, Hertel S, Johnston M, Molojavyi A, Dries V, Varga G, Van Rooijen N, Kochanek S (2003) A hemodynamic response to intravenous adenovirus vector particles is caused by systemic Kupffer cell-mediated activation of endothelial cells. Hum Gene Ther 14: 1631–1641.
  • Shi CX, Hitt M, Ng P, Graham FL (2002) Superior tissuespecific expression from tyrosinase and prostate-specific antigen promoters/enhancers in helper-dependent compared with first-generation adenoviral vectors. Hum Gene Ther 13: 211–224.
  • Shi CX, Long MA, Liu L, Graham FL, Gauldie J, Hitt MM (2004) The human SCGB2A2 (mammaglobin-1) promoter/ enhancer in a helper-dependent adenovirus vector directs high levels of transgene expression in mammary carcinoma cells but not in normal nonmammary cells. Mol Ther 10: 758–767.
  • Soifer HS, Kasahara N (2004) Retrotransposon-adenovirus hybrid vectors: efficient delivery and stable integration of transgenes via a two-stage mechanism. Curr Gene Ther 4: 373–384.
  • Soifer H, Higo C, Kazazian HH, Moran JV, Mitani K, Kasahara N (2001) Stable integration of transgenes delivered by a retrotransposon-adenovirus hybrid vector. Hum Gene Ther 12: 1417–1428.
  • Soifer H, Higo C, Logg CR, Jih LJ, Shichinohe T, Harboe- Schmidt E, Mitani K, Kasahara N (2002) A novel, helper-dependent, adenovirus-retrovirus hybrid vector: stable transduction by a two-stage mechanism. Mol Ther 5: 599–608.
  • Soudais C, Skander N, Kremer EJ (2004) Long-term in vivo transduction of neurons throughout the rat CNS using novel helper-dependent CAV-2 vectors. FASEB J 18: 391–393.
  • Stilwell JL, McCarty DM, Negishi A, Superfine R, Samulski RJ (2003) Development and characterization of novel empty adenovirus capsids and their impact on cellular gene expression. J Virol 77: 12881–21885.
  • Takahashi K, Saishin Y, Saishin Y, Silva RL, Oshima Y, Oshima S, Melia M, Paszkiet B, Zerby D, Kadan MJ, Liau G, Kaleko M, Connelly S, Luo T, Campochiaro PA (2003) Intraocular expression of endostatin reduces VEGFinduced retinal vascular permeability, neovascularization, and retinal detachment. FASEB J 17: 896–898.
  • Toietta G, Pastore L, Cerullo V, Finegold M, Beaudet AL, Lee B (2002) Generation of helper-dependent adenoviral vectors by homologous recombination. Mol Ther 5: 204–210.
  • Umana P, Gerdes CA, Stone D, Davis JR, Ward D, Castro MG, Lowenstein PR (2001) Efficient FLPe recombinase enables scalable production of helper-dependent adenoviral vectors with negligible helper-virus contamination. Nat Biotechnol 19: 582–585.
  • Wang Y, Huang S (2000) Adenovirus technology for gene manipulation and functional studies. Drug Disc Today 5: 10–16.
  • Wang L, Hernandez-Alcoceba R, Shankar V, Zabala M, Kochanek S, Sangro B, Kramer MG, Prieto J, Qian C (2004) Prolonged and inducible transgene expression in
  • the liver using gutless adenovirus: a potential therapy for liver cancer. Gastroenterology 126: 278–289.
  • Wen S, Graf S, Massey PG, Dichek DA (2004) Improved vascular gene transfer with a helper-dependent adenoviral vector. Circulation 110: 1484–1491.
  • Wickham TJ, Mathias P, Cheresh DA, Numerow GR (1993) Integrins αvβ3 and αvβ5 promote adenovirus internalization but not virus attachment. Cell 73: 309–319.
  • Wilmott R, Amin RS, Perez CR, Wert SEM, Keller G, Boivin GP, Hirsch R, De Inocencio J, Lu P, Reising SF, Yei S, Whitsett JA, Trapnell BC (1996) Safety of adenovirusmediated transfer of the human cystic fibrosis transmembrane conductance regulator cDNA to the lungs of nonhuman primates. Hum Gene Ther 6: 301–318.
  • Yant SR, Ehrhardt A, Mikkelsen JG, Meuse L, Pham T, Kay MA (2002) Transposition from a gutless adeno-transposon vector stabilizes transgene expression in vivo. Nat Biotechnol 20: 999–1005.
  • Ye X, Robinson MB, Pabin C, Quinn T, Jawad A, Wilson JM, Batshaw ML (1997) Adenovirus-mediated in vivo gene transfer rapidly protects ornithine transcarbamylase-deficient mice from an ammonium challenge. Pediatr Res 41: 527–534.
  • Zerby D, Sakhuja K, Reddy PS, Zimmerman H, Kayda D, Ganesh S, Pattison S, Brann T, Kadan MJ, Kaleko M, Connelly S (2003) In vivo ligand-inducible regulation of gene expression in a gutless adenoviral vector system. Hum Gene Ther 14: 749–761.
  • Zhang HG, Zhou T, Yang P, Edwards CK III, Curiel DT, Moutz DM (1998) Inhibition of TNFα decreases inflammation and prolongs adenovirus gene expression in lung and liver. Hum Gene Ther 9: 1875–1884.
  • Zhou H, Zhao T, Pastore L, Nageh M, Zheng W, Rao XM, Beaudet AL (2001) A Cre-expressing cell line and an E1/E2a double-deleted virus for preparation of helperdependent adenovirus vector. Mol Ther 3: 613–622.
  • Zou L, Zhou H, Postore L, Yang K (2000) Prolonged transgene expression mediated by a helper-dependent adenoviral vector in the central nervous system. Mol Ther 2: 105–113.
  • Zou L, Yuan X, Zhou H, Lu H, Yang K (2001) Helper-dependent adenoviral vector-mediated gene transfer in aged rat brain. Hum Gene Ther 12: 181–191.
Typ dokumentu
Bibliografia
Identyfikatory
Identyfikator YADDA
bwmeta1.element.agro-article-d09dd6c8-488b-47d1-b97c-24be9699ab40
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.